Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Liabilities and Shareholders Equity (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Liabilities and Shareholders Equity for 9 consecutive years, with $563.8 million as the latest value for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity changed N/A year-over-year to $563.8 million; the TTM value through Dec 2025 reached $1.8 billion, changed N/A, while the annual FY2025 figure was $563.8 million, N/A changed from the prior year.
  • Liabilities and Shareholders Equity hit $563.8 million in Q4 2025 for Soleno Therapeutics, down from $599.9 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $599.9 million in Q3 2025 and bottomed at $318.1 million in Q1 2025.